Public consultation on proposed amendments to the Poisons Standard - ACMS/ACCS/Joint ACMS-ACCS, March 2022

Closed 31 Jan 2022

Opened 20 Dec 2021

Contact

Medicines Scheduling

1800 020 653

medicines.scheduling@health.gov.au

Feedback updated 12 Jul 2023

We asked

Between 20 December 2021 to 31 January 2022, we sought submissions from the public on scheduling proposals referred to the March 2022 meetings of the Advisory Committees on Medicines and Chemicals Scheduling. Respondents were given the choice to indicate their support or opposition to the proposed amendments using survey buttons, with or without a written response.

You said

Azelastine and fluticasone: A total of 25 responses were received for azelastine and fluticasone, 11 in support, 1 in partial support and 13 in opposition of the proposed amendment. Of these responses, 2 submissions in support, 1 submission in partial support, and 1 submission opposing the proposed amendments contained a written component.

Cannabis and THC: A total of 56 responses were received for cannabis and THC, 29 in support, 16 in partial support and 11 in opposition of the proposed amendments. Of these responses, 3 submissions in support, 1 submission in partial support, and 2 submissions opposing the proposed amendments contained a written component.

Lead: A total of 28 responses were received for lead, 14 in support, 1 in partial support and 13 in opposition of the proposed amendments. Of these responses, 1 submission in support, 1 submission in partial support, and 4 submissions opposing the proposed amendments contained a written component.

Meloxicam: A total of 393 responses were received for meloxicam, a large proportion of which were identical submissions as part of a campaign. Of these responses, 23 were in support, 1 in partial support and 369 in opposition of the proposed amendments. 10 submissions in support, 1 submission in partial support, and 132 submissions opposing the proposed amendments contained a written component.

Lidocaine: A total of 479 responses were received for lidocaine, a significant amount of which contained campaign wording. Of the responses, 188 were in support of the proposed amendments, 1 in partial support and 290 in opposition. 62 of submissions in support and 121 submissions opposing the proposed amendments contained a written component.

Flumioxazin (private application): A total of 16 responses were received for the flumioxazin (private) proposal, 5 in support, 2 in partial support and 9 in opposition. Of these submissions, only 1 response in opposition contained a written component.

Flumioxazin (APVMA): A total of 16 responses were received for the flumioxazin (APVMA) proposal, 6 in support, 2 in partial support and 8 in opposition. Of these submissions, 1 submission in support and 1 submission in opposition contained a written component.

We did

The Delegate considered all submissions prior to making their interim decisions on these substances. The interim decisions were published on 19 August 2022. Following another round of public consultations the final decisions for these substances were be published on 18 November 2022.

Published responses

View submitted responses where consent has been given to publish the response.

Overview

Scheduling amendments referred to expert advisory committee

This consultation is for applications and delegate initiated proposals to amend the Poisons Standard. The scheduling amendments and any submissions received will be considered at the 15-17 March 2022 meetings of the Advisory Committee on Medicines Scheduling (ACMS) and the Advisory Committee on Chemicals Scheduling (ACCS).

The closing date for this consultation is close of business 31 January 2022. All submissions received by the deadline will be considered by the delegate before they make an interim decision.

The proposals under consultation are detailed in the public notice of December 2021.

Substances for which public comment is sought

  • Item 1.1 - Azelastine and fluticasone propionate
  • Item 2.1 - Cannabis and tetrahydrocannabinols
  • Item 2.2 - Lead
  • Item 2.3 - Meloxicam
  • Item 2.4 - Lidocaine 
  • Item 3.1 - Flumioxazin (private application)
  • Item 3.2 - Flumioxazin (second application)

What happens next

All public submissions will be published on the TGA website at Public submissions on scheduling matters, unless marked confidential or indicated otherwise in the submission information (see Privacy and your Personal information).

Public submissions are an important part of the process for amending the Poison Standard, and are published on the TGA website using the consultation hub.  Submissions by the public may not reflect the views of the Department of Health or TGA.  Published submissions should not be taken as being endorsed by the Department or TGA.

Following consideration of public submissions received before the closing date and advice from the expert advisory committee/s, decisions on the proposed amendments are anticipated to be published as interim decisions on the TGA website: Scheduling delegate's interim decisions & invitations for further comment in June 2022.

Audiences

  • General public

Interests

  • Legislation